Cancer Treatment Today

Ponatinib (Iclusig, AP24534) was recently FDA approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). It was approved based on the inital results of The PACE (Ponatinb Ph+ ALL and CML Evaluation) trial. B ecasue it not only attacks the CML mutation, BCR-ABL (including the T315I that other drugs doen affect it is an attarctive candidate for personalized use in conditions

Ponatinib (Iclusig, AP24534) was FDA approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). It was approved based on the inital results of The PACE (Ponatinb Ph+ ALL and CML Evaluation) trial  and has activity against the T315I mutation, which confers resistant to other CML drugs. It targets the Bcr-Abl tyrosine kinase, as well as VEGFR, PDGFR, FGFR, the SRC kinases,

Glomus tumors are rare, slow-growing, vascular tumors that have been reported in various areas of the body. They are are  paragangliomas, and are more common in in women in their fifties and sixties. Because of its rarity, not much can be said about this cancer's treatment.  Alpha-blockers and beta-blockers  can be used for, especially preoperatively to stabilize blood pressure and cardiac arrhythmias. Successful treatment of pulmonary metastases

Megace has long been shown to help weight gain in cancer and AIDS. More recently, Megace ES came on the market. The advantage is in the concentrated dose that Megace ES offers. It is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). The recommended adult initial dosage of Megace ES (megestrol acetate) oral suspension is 625 mg/day

The advantage is in the concentrated dose that Megace ES offers in contrast to Megace. Megace ES (megestrol acetate) oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). The recommended adult initial dosage of Megace ES (megestrol acetate) oral suspension is 625 mg/day (5 mL/day or one teaspoon daily). The equicaletn

Among the reffects of Snadostatin is  reduction of blood flow to the Go tract, and inhibition of release of several gastrointestinal hormones, which might decrease leaking from fistulas after surgery and help them heal. Several studies and a meta-analysis looked at this effect.  UNfortunately, the results are mixed and not entirely convincing. A recent Cochrane review of somatostatin analogues (SSAs) for pancreatic surgery concluded that SSAs reduce

The principal effects of octreotide include inhibition of growth hormone (GH), glucagon, and insulin. However, there are other effects that have been attemtped to be exploited to therapeutic ends, including to help heal pancreatic and gastreointeistinal fistulas.  Among themare reduction of splanchnic blood flow, and inhibition of release of several gastrointestinal hormones, including serotonin, gastrin, vasoactive intestinal peptide, secretin,

Fluoropyrimidine (5-fluorouracil [5-FU] is the oldest chemotherapy drug for colon cancer and it is usually given with leucovorin [LV]. , It has a long history of its use for colorectal metastatic cancer and support from many older papers. Unfortunately, the issue ofweekly versus every three weeks schedule for 5FU.leukovorin has not been resolved, and with the appearance of many new drugs, has receded into the past and is no longer of actual importance

Fluoropyrimidine (5-fluorouracil [5-FU] is the oldest chemotherapy drug for colon cancer and it is usually given with leucovorin [LV]. For second or third line therapy, single agents are acceptable  and NCCN has a complex schema when to give what for second line and also lists Erbitux and Vectbix. Capecitabine is also FDA approved as a single agent. NCCN does not list 5FU/Leukovorin but it can also be considered appropriate given the long history

Granular cell tumor develops on any skin or mucosal surface, but occurs most commonly on the tongue( 40%).  It sometimes behaves like a benign tumor and sometimes as a malignancy. Other names for this rare cancer are:  Abrikossoff's tumor, Granular cell myoblastoma, Granular cell nerve sheath tumor, and Granular cell schwannoma. It is now believed that it is a cancerous process, even when it behaves like a benign cancer, and it can always begin